World's Best Scientists 2026 revealed!
Giovanni Barosi

Giovanni Barosi

D-Index & Metrics

Medicine

D-Index
93
Citations
35316
World Ranking
10799
National Ranking
385

Overview

Giovanni Barosi is affiliated with the University of Pavia in Italy and has a research profile centered predominantly in the field of Medicine. Their work spans multiple subfields including Genetics, Hematology, Rheumatology, Molecular Biology, and Oncology, reflecting a broad engagement with both clinical and molecular aspects of medical science.

The primary focus of Barosi's research lies in hematological malignancies and related disorders. Their main topics of investigation include:

  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Eosinophilic Disorders and Syndromes
  • Acute Myeloid Leukemia Research
  • Chronic Myeloid Leukemia Treatments
  • Multiple Myeloma Research and Treatments
  • Kruppel-like factors research
  • Chronic Lymphocytic Leukemia Research

Their publication record shows a strong presence in specialized hematology and oncology journals. Frequent venues for their research outputs include:

  • Haematologica
  • Blood
  • Hematological Oncology
  • Blood Advances
  • Leukemia

Among recent publications authored or coauthored by Giovanni Barosi are:

  • Rabbit ATG/ATLG in preventing graft-versus-host disease after allogeneic stem cell transplantation: consensus-based recommendations by an international expert panel, 2020, Bone Marrow Transplantation
  • Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group, 2023, The Lancet Haematology
  • 2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde, 2021, Haematologica
  • Thrombosis in multiple myeloma: risk stratification, antithrombotic prophylaxis, and management of acute events. A consensus-based position paper from an ad hoc expert panel, 2022, Haematologica
  • Duration of Response to Luspatercept in Patients (Pts) Requiring Red Blood Cell (RBC) Transfusions with Myelofibrosis (MF) - Updated Data from the Phase 2 ACE-536-MF-001 Study, 2020, Blood

Collaborations form an integral component of Barosi's research activity. Frequently appearing coauthors include:

  • Vittorio Rosti
  • Robert Peter Gale
  • Margherita Massa
  • Rita Campanelli
  • Paolo Catarsi

This body of work and collaboration network supports Giovanni Barosi's sustained contribution to the field of hematology, with an emphasis on myeloproliferative disorders, stem cell transplantation, and hematologic malignancies.

Best Publications

  • JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.

    Claire Harrison;Jean Jacques Kiladjian;Haifa Kathrin Al-Ali;Heinz Gisslinger

  • New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.

    Francisco Cervantes;Brigitte Dupriez;Arturo Pereira;Francesco Passamonti

  • Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet

    Tiziano Barbui;Giovanni Barosi;Gunnar Birgegard;Francisco Cervantes

  • Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.

    Ayalew Tefferi;Juergen Thiele;Attilio Orazi;Hans Michael Kvasnicka

  • Mutations and prognosis in primary myelofibrosis

    Alessandro Maria Vannucchi;Tl Lasho;Paola Guglielmelli;Flavia Biamonte

  • Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia.

    Alessandro M. Vannucchi;Elisabetta Antonioli;Paola Guglielmelli;Alessandro Rambaldi

  • Philadelphia chromosome-negative classical myeloproliferative neoplasms: Revised management recommendations from European LeukemiaNet

    Tiziano Barbui;Ayalew Tefferi;Alessandro M. Vannucchi;Francesco Passamonti

  • MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis.

    Paola Guglielmelli;Terra L. Lasho;Giada Rotunno;Mythri Mudireddy

  • Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs

    Robyn M. Emanuel;Amylou C. Dueck;Holly L. Geyer;Jean Jacques Kiladjian

  • Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy : results of a consensus process by an International Working Group

    Tapani Ruutu;Giovanni Barosi;Richard J. Benjamin;Richard E. Clark

  • Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis

    Francisco Cervantes;Alessandro M. Vannucchi;Jean Jacques Kiladjian;Haifa Kathrin Al-Ali

  • Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis

    Elisa Rumi;Daniela Pietra;Cristiana Pascutto;Paola Guglielmelli

  • Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment.

    G. Barosi;R. A. Mesa;J. Thiele;F. Cervantes

  • Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report

    Ayalew Tefferi;Francisco Cervantes;Ruben Mesa;Francesco Passamonti

  • Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT).

    Ruben A. Mesa;Srdan Verstovsek;Francisco Cervantes;Giovanni Barosi

  • The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients

    Robyn Scherber;Amylou C. Dueck;Peter Johansson;Tiziano Barbui

  • Interpretation of measured red cell mass and plasma volume in adults: Expert Panel on Radionuclides of the International Council for Standardization in Haematology.

    T. C. Pearson;D. L. Guthrie;J. Simpson;S. Chinn

  • Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation

    Tiziano Barbui;Giovanni Barosi;Alberto Grossi;Luigi Gugliotta

  • International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).

    Ayalew Tefferi;Giovanni Barosi;Ruben A. Mesa;Francisco Cervantes

  • The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients.

    Paola Guglielmelli;Terra L. Lasho;Giada Rotunno;Joannah Score

Frequent Co-Authors

Alessandro M. Vannucchi
Alessandro M. Vannucchi University of Florence
Tiziano Barbui
Tiziano Barbui FROM-Fondazione per la Ricerca Ospedale di Bergamo
Alessandro Rambaldi
Alessandro Rambaldi University of Milan
Paola Guglielmelli
Paola Guglielmelli University of Florence
Francesco Passamonti
Francesco Passamonti University of Milan
Francisco Cervantes
Francisco Cervantes University of Barcelona
Claire N. Harrison
Claire N. Harrison Guy's and St Thomas' NHS Foundation Trust
Ruben A. Mesa
Ruben A. Mesa The University of Texas Health Science Center at San Antonio
Mario Cazzola
Mario Cazzola University of Pavia
Sante Tura
Sante Tura University of Bologna

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re interested in the wider healthcare field beyond medical school, there are various flexible online degrees and career pathways available. For those wanting to enter nursing quickly, fast track LPN programs online offer an accelerated route into Licensed Practical Nursing, allowing you to start your healthcare journey sooner.

Mental health professionals are in demand, and advanced nursing degrees like online MSN PMHNP programs can prepare you for a specialized career as a Psychiatric Mental Health Nurse Practitioner, all through online study.

Those interested in the business and administration side of healthcare can pursue a health care administration online degree. These programs are ideal for students looking to manage healthcare organizations or clinics, and prepare you for dynamic leadership roles.

For advanced administrative roles, consider the cheapest online MHA programs, which deliver affordable graduate-level education for aspiring healthcare administrators. With these online degrees, you can develop specialized expertise and open up a range of rewarding career opportunities in healthcare management and beyond.

Best Scientists Citing Giovanni Barosi

Trending Scientists